Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6

CNS Pharmaceuticals (NASDAQ:CNSP) is backmost connected each biotech watchlist aft a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here's what you should really beryllium watching.

Holders captured the move; caller entrants look tougher mathematics from here. The marketplace headdress sits astatine astir $6.36 million, the institution reported a Q1 2024 nett nonaccomplishment of $3.50 cardinal with currency collapsed to astir $800,000, and the banal is inactive disconnected 42.18% implicit 1 twelvemonth and efficaciously 100% implicit 5 years connected a split-adjusted basis. The defining catalyst, Berubicin topline data, was already telegraphed for the archetypal fractional of 2025. This week's determination resolves that catalyst alternatively than anticipating it. Pre-revenue, single-asset, cash-starved binaries transportation concentrated hazard profiles that compound aft a triple-digit week.

The smarter redirects beryllium successful the aforesaid cardinal tense strategy oncology lane with deeper pipelines, existent funding, and commercialized traction the assemblage has not priced in.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Neonc Technologies wasn't 1 of them. Get them present FREE.

NeOnc Technologies (NASDAQ:NTHI) is the clinical-data redirect. NEO100 successful recurrent encephalon crab posted a 21% effect complaint against a humanities mean beneath 8%, with 44% of patients reaching six-month progression-free endurance versus a 21% to 31% humanities band. The FDA cleared NEO212 for Phase II, the NIH layered successful $2.5 cardinal of non-dilutive funding, and a $50 cardinal strategical concern with Quazar Investment opens a Middle East transmission done the NuroMENA subsidiary. Patents licensed from USC tally to 2038. Shares are down 49.94% twelvemonth to date, the expert people stands astatine $15 against a existent punctuation of $4.14, and the adjacent net study lands May 8, 2026.

Plus Therapeutics (NASDAQ:PSTV) is the commercial-traction redirect. The CNSide diagnostic present carries nationalist sum with UnitedHealthcare and Humana for a combined astir 67 cardinal covered lives, holds CLIA certification, and is licensed successful 49 of 50 states. Plus secured an AMA Category III CPT reimbursement code, a $17.6 cardinal CPRIT grant, and a $3 cardinal DoD pediatric encephalon crab grant. ReSPECT-LM information is targeted for Q3 2026 and ReSPECT-GBM for Q4 2026, with absorption guiding to breakeven by 2027. Q3 2025 EPS came successful astatine -$0.04 against a -$0.70 estimate, a 94.29% beat. The Wall Street mean people sits astatine $38 against today's $6.30 quote.